NEW ORLEANS (EGMN) - Melphalan showed itself to be a better partner than thalidomide for induction with bortezomib in a randomized phase III trial with important implications for the treatment of elderly patients with multiple myeloma.Investigators from the Spanish Myeloma Group modified the intensity of what has come to be known as the VISTA regimen in the trial. Instead of receiving bortezomib (Velcade) twice a week as part of a combination regimen, 260 patients (median age, 75 years) were given...